ATE316136T1 - Nierenpolycystose-gen - Google Patents

Nierenpolycystose-gen

Info

Publication number
ATE316136T1
ATE316136T1 AT95938775T AT95938775T ATE316136T1 AT E316136 T1 ATE316136 T1 AT E316136T1 AT 95938775 T AT95938775 T AT 95938775T AT 95938775 T AT95938775 T AT 95938775T AT E316136 T1 ATE316136 T1 AT E316136T1
Authority
AT
Austria
Prior art keywords
gene
pkd1
polycystosis
renal
cyst formation
Prior art date
Application number
AT95938775T
Other languages
English (en)
Inventor
Katherine W Klinger
Gregory M Landes
Timothy C Burn
Timothy D Connors
William Dackowski
Gregory Germino
Feng Qian
Original Assignee
Genzyme Corp
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/323,443 external-priority patent/US5654170A/en
Application filed by Genzyme Corp, Univ Johns Hopkins filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE316136T1 publication Critical patent/ATE316136T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
AT95938775T 1994-10-12 1995-10-11 Nierenpolycystose-gen ATE316136T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/323,443 US5654170A (en) 1994-10-12 1994-10-12 Polycystic kidney disease gene
US38152095A 1995-01-31 1995-01-31

Publications (1)

Publication Number Publication Date
ATE316136T1 true ATE316136T1 (de) 2006-02-15

Family

ID=26983965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95938775T ATE316136T1 (de) 1994-10-12 1995-10-11 Nierenpolycystose-gen

Country Status (10)

Country Link
US (1) US6867288B1 (de)
EP (1) EP0782630B1 (de)
AT (1) ATE316136T1 (de)
AU (1) AU706167B2 (de)
CA (1) CA2202283A1 (de)
DE (1) DE69534753T2 (de)
DK (1) DK0782630T3 (de)
ES (1) ES2256851T3 (de)
PT (1) PT782630E (de)
WO (1) WO1996012033A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824767B2 (en) * 1994-11-07 2004-11-30 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6599719B2 (en) * 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
JP2002503952A (ja) * 1996-05-24 2002-02-05 ジェンザイム・コーポレーション 多嚢胞性腎疾患遺伝子
DE19650758C1 (de) * 1996-12-06 1998-01-02 Deutsches Krebsforsch PKD1-Fragmente mit Bindungsregionen für PKD1-spezifische Antikörper
US6399349B1 (en) * 1997-09-02 2002-06-04 James W. Ryan Human aminopeptidase P gene
US7553644B2 (en) 2000-07-13 2009-06-30 The Johns Hopkins University School Of Medicine Detection and treatment of polycystic kidney disease
CA2993381C (en) 2006-07-24 2020-07-14 Athena Diagnostics, Inc. Method of detecting the occurrence of adpkd based on presence of nucleotide sequence alteration in pkd1
US8424594B2 (en) * 2007-12-10 2013-04-23 Presto Engineering, Inc. Apparatus for thermal control in the analysis of electronic devices
WO2012110999A1 (en) * 2011-02-16 2012-08-23 Compugen Ltd Genetic markers for prognosis of rheumatoid arthritis treatment efficacy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018225A1 (en) * 1993-12-24 1995-07-06 Medical Research Council Polycystic kidney disease 1 gene and uses thereof
EP0777728A1 (de) * 1994-06-14 1997-06-11 Medical Research Council Polyzystisches nierenkrankheits-1-gen und verwendung davon
US6071717A (en) * 1995-01-31 2000-06-06 Genzyme Corporation Polycystic kidney disease gene and protein

Also Published As

Publication number Publication date
DK0782630T3 (da) 2006-05-29
DE69534753D1 (de) 2006-04-06
US6867288B1 (en) 2005-03-15
JP4495255B2 (ja) 2010-06-30
EP0782630B1 (de) 2006-01-18
JP2001520502A (ja) 2001-10-30
EP0782630A4 (de) 1997-12-17
AU706167B2 (en) 1999-06-10
EP0782630A1 (de) 1997-07-09
CA2202283A1 (en) 1996-04-25
WO1996012033A1 (en) 1996-04-25
PT782630E (pt) 2006-06-30
DE69534753T2 (de) 2006-11-02
AU4002795A (en) 1996-05-06
ES2256851T3 (es) 2006-07-16

Similar Documents

Publication Publication Date Title
PT1032662E (pt) Metodos e composicoes para imunomodulacao.
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
MX9602570A (es) Metodos y materiales anti-fungosos.
ATE257390T1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
AU5229498A (en) Mutants of the lag-3 proteins, products for the expression of these mutants and use
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69731463D1 (de) Rekombinante ribonuklease proteine
DE69534753D1 (de) Nierenpolycystose-gen
ATE249835T1 (de) Immunoregulator
FI961584A0 (fi) C-reaktiivisista proteiinifragmenteista johdetut oligopeptidit
ES2013321A6 (es) Un metodo de produccion de anticuerpos monoclonales
PT938329E (pt) Composicao de tlp imunogenica
DE69837808D1 (de) pRb2/p130 PEPTIDINHIBITOREN DER cdk2 KINASEAKTIVITÄT
BR0113266A (pt) Métodos para modular proteìnas quinase de linhagem múltipla e compostos protetores que modulam proteìnas quinase de linhagem múltipla
ATE103930T1 (de) Modifizierte proteine.
NZ334762A (en) Human DNase I variants having binding affinity to actin
GB2374871A (en) Peptide fragments of colostrinin and their use
GB9723824D0 (en) Cytostatic agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0782630

Country of ref document: EP